Valuation: Silence Therapeutics plc

Market Cap 358M 478M 419M 387M 679M 45.46B 691M 4.64B 1.8B 22.41B 1.79B 1.76B 77.64B P/E 2026 *
-17x
P/E 2027 * -15.1x
Enterprise Value 212M 283M 248M 229M 402M 26.88B 408M 2.74B 1.07B 13.25B 1.06B 1.04B 45.91B EV / Sales 2026 *
84.9x
EV / Sales 2027 * 31.7x
Free-Float
69.36%
Yield 2026 *
-
Yield 2027 * -
1 day-4.06%
1 week-7.56%
Current month-7.56%
1 month+64.51%
3 months+81.25%
6 months+75.00%
Current year+66.94%
1 week 10.1
Extreme 10.1
11.06
1 month 5.88
Extreme 5.88
11.06
Current year 4.19
Extreme 4.19
11.06
1 year 4.19
Extreme 4.19
11.06
3 years 1.97
Extreme 1.97
27.72
5 years 1.97
Extreme 1.97
27.72
10 years 1.97
Extreme 1.97
35
Manager TitleAgeSince
Chief Executive Officer 72 2025-12-13
Director of Finance/CFO 54 2022-02-20
Chief Tech/Sci/R&D Officer - 2020-12-31
Director TitleAgeSince
Director/Board Member 63 2018-06-20
Chairman 72 2019-11-30
Director/Board Member 54 2025-12-17
Date Insider Type Main position Quantity % Market Cap.
01-01Free

Director

90,000 0.0635%
01-01Free

Chief Technology Officer

300,000 0.2117%
01-01Free

Chief Financial Officer

375,000 0.2646%
Change 5-day change 1-year change 3-year change Capi.($)
-4.06%-7.56%+77.14%+77.14% 500M
-1.03%+5.24%+2.94%+9.41% 50.25B
+0.25%+1.70%+419.39%+621.71% 40.39B
+1.10%+7.77%+28.18%-3.96% 34.38B
-0.16%+8.12%+27.85%+62.55% 34.4B
+1.31%-0.56%+5.12%+33.90% 26.32B
-0.35%+0.09% - - 16.64B
-3.33%+3.15%+71.30%+131.94% 16.14B
+0.32%+0.53%+14.33%+21.47% 13.71B
+3.79%+8.88%+106.63%+106.63% 13.75B
Average -0.24%+3.25%+83.65%+117.86% 24.65B
Weighted average by Cap. +0.04%+4.99%+95.72%+141.06%

Financials

2026 *2027 *
Net sales 2.5M 3.33M 2.92M 2.69M 4.73M 317M 4.81M 32.29M 12.56M 156M 12.5M 12.24M 541M 3.44M 4.59M 4.03M 3.71M 6.52M 436M 6.63M 44.53M 17.31M 215M 17.23M 16.87M 745M
Net income -50.34M -67.21M -58.91M -54.34M -95.43M -6.39B -97.02M -651M -253M -3.15B -252M -247M -10.91B -84.67M -113M -99.08M -91.4M -160M -10.74B -163M -1.1B -426M -5.3B -424M -415M -18.34B
Net Debt -146M -196M -171M -158M -278M -18.58B -282M -1.9B -737M -9.16B -733M -718M -31.72B -249M -333M -292M -269M -473M -31.64B -481M -3.23B -1.26B -15.6B -1.25B -1.22B -54.04B
Logo Silence Therapeutics plc
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Employees
88
Date Price Change Volume
26-07-07 US$10.15 -4.06% 617,557
26-07-06 US$10.58 +1.83% 578,918
26-07-02 US$10.39 -1.05% 696,727
26-07-01 US$10.50 -4.37% 718,986
26-06-30 US$10.98 +1.76% 556,751
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
10.15USD
Average target price
29.17USD
Spread / Average Target
+187.36%

Quarterly revenue - Rate of surprise